Physician profile
Daniel C Connell
NPI 1326138884
$5,502.25
in general payments reported to CMS, 2019-2025
27 companies · $813 in 2025
The $813 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $370 · 2021: $260 · 2022: $1,047 · 2023: $969 · 2024: $1,362 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,144.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,231.49 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Celgene Corporation | $428.89 | 2021-2024 | Zeposia |
| Pfizer INC. | $356.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $354.69 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $314.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $270.69 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.75 | 2019-2025 | Xifaxan, Plenvu |
| Intercept Pharmaceuticals, INC. | $141.09 | 2019-2024 | |
| Genzyme Corporation | $127.79 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $122.09 | 2024 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $106.50 | 2020-2024 | |
| Covidien LP | $106.49 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $96.56 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $92.32 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $80.71 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $76.29 | 2022-2025 | Rebyota |
| Gilead Sciences, INC. | $62.77 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $62.14 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $58.21 | 2024 | Iqirvo, Bylvay |
| Lilly USA, LLC | $41.49 | 2024-2025 | Omvoh |
| Blueprint Medicines Corporation | $26.08 | 2023 | |
| Celltrion USA INC. | $24.23 | 2025 | Vegzelma |
| Amgen INC. | $22.68 | 2023 | Amjevita |
| Ardelyx, INC. | $19.54 | 2024 | Ibsrela |
| Sandoz INC. | $18.17 | 2024 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2022 | |
| Daiichi Sankyo INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Connell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.